NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
16 July 2025
| Name: | MESOBLAST LIMITED (MSB) |
| ISIN: | AU000000MSB8 |
| Date of Listing: | 16 December 2004 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 109 431 870ABN: 68 109 431 870
Registration Date: 08 June 2004
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
MUFG Corporate Markets Limited (was Link Market Services)
Liberty Place Level 41 161 Castlereagh St Sydney NSW 2000
Locked Bag A14 Sydney South NSW 1235
Tel : 1300 554 474
Fax : (02) 9287 0303 or (02) 9287 0309 (for voting)
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Mesoblast Limited will be lifted immediately following the release by MSB of an announcement regarding a private placement. | 26/04/2023 |
The company releases a notice of proposed issue of securities. | 26/04/2023 |
The company has completed a global private placement primarily to Mesoblast's existing major US, UK, and Australian shareholders raising approximately US$40 million, net of transaction costs, at A$0.85 per share. | 26/04/2023 |
The securities of Mesoblast Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MSB, pending the release of an announcement regarding a private placement. | 24/04/2023 |
The suspension of trading in the securities of Mesoblast Limited will be lifted immediately following the release by MSB of an announcement regarding a capital raising. | 09/08/2022 |
The company has completed a US$45 million (A$65 million) financing via the issue of 86.7 million fully-paid, ordinary shares in a global private placement led by its largest shareholder, M&G Investments, United Kingdom, and strongly supported by its major Australian and American shareholders. The private placement was made at A$0.75 per share, a 5% discount to the thirty trading-day volume weighted average price (VWAP), without any associated warrants or options. Inclusive of the US$45 million private placement, pro-forma cash-on-hand at June 30, 2022 is approximately US$105.5 million. | 09/08/2022 |
The securities of Mesoblast Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MSB, pending the release of an announcement regarding a capital raising. | 08/08/2022 |
The securities of Mesoblast Limited (the "Company") will be reinstated to quotation immediately, following the release of an announcement by the Company. | 14/06/2016 |
The company provides an update on its global heart failure program. | 14/06/2016 |
The company advises that the suspension of trading in its securities will remain in place pending an announcement regarding material corporate developments with respect to certain assets of the Company. The Company expects the voluntary suspension to remain in place until the earlier of the commencement of trading on 14 June 2016 and the Company making an announcement with respect to the corporate developments. | 10/06/2016 |
The securities of Mesoblast Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company. | 03/06/2016 |
The securities of Mesoblast Limited (the "Company") will be reinstated to quotation immediately, following the release of an announcement by the Company. Security Code: MSB | 16/11/2015 |
Mesoblast Limited (ASX:MSB; NASDAQ:MESO) today announced it had listed on the Nasdaq Global Market on 13 November under the symbol "˜MESO | 16/11/2015 |
Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has filed a US registration statement on Form F-1 with the U.S. Securities and Exchange Commission, offering 5,742,510 American Depositary Shares (ADSs) in the United States, with each ADS representing five fully paid ordinary shares of Mesoblast (Shares). The actual number of ADSs and the issue price, in U.S. dollars, will be determined by Mesoblast in conjunction with the Company's underwriters at the conclusion of the offer process. | 03/11/2015 |
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) announced today that it plans to conduct a registered initial public offering in the United States. Mesoblast has previously submitted to the U.S. Securities and Exchange Commission (the "SEC") a draft registration statement. Mesoblast intends to publicly file its registration statement with the SEC and commence the offering next week. | 30/10/2015 |
The company lodges its quarterly report. | 30/10/2015 |
The securities of Mesoblast Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company. Security Code: MSB | 30/10/2015 |
shares reinstated to quotation | 12/05/2010 |
the securities of Mesoblast Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company | 05/05/2010 |
The suspension of trading in the securities of Mesoblast Limited will be lifted immediately following the release by MSB of an announcement regarding a private placement. | 26/04/2023 |
The company releases a notice of proposed issue of securities. | 26/04/2023 |
The company has completed a global private placement primarily to Mesoblast's existing major US, UK, and Australian shareholders raising approximately US$40 million, net of transaction costs, at A$0.85 per share. | 26/04/2023 |
The securities of Mesoblast Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MSB, pending the release of an announcement regarding a private placement. | 24/04/2023 |
The suspension of trading in the securities of Mesoblast Limited will be lifted immediately following the release by MSB of an announcement regarding a capital raising. | 09/08/2022 |
The company has completed a US$45 million (A$65 million) financing via the issue of 86.7 million fully-paid, ordinary shares in a global private placement led by its largest shareholder, M&G Investments, United Kingdom, and strongly supported by its major Australian and American shareholders. The private placement was made at A$0.75 per share, a 5% discount to the thirty trading-day volume weighted average price (VWAP), without any associated warrants or options. Inclusive of the US$45 million private placement, pro-forma cash-on-hand at June 30, 2022 is approximately US$105.5 million. | 09/08/2022 |
The securities of Mesoblast Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MSB, pending the release of an announcement regarding a capital raising. | 08/08/2022 |
The securities of Mesoblast Limited (the "Company") will be reinstated to quotation immediately, following the release of an announcement by the Company. | 14/06/2016 |
The company provides an update on its global heart failure program. | 14/06/2016 |
The company advises that the suspension of trading in its securities will remain in place pending an announcement regarding material corporate developments with respect to certain assets of the Company. The Company expects the voluntary suspension to remain in place until the earlier of the commencement of trading on 14 June 2016 and the Company making an announcement with respect to the corporate developments. | 10/06/2016 |
The securities of Mesoblast Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company. | 03/06/2016 |
The securities of Mesoblast Limited (the "Company") will be reinstated to quotation immediately, following the release of an announcement by the Company. Security Code: MSB | 16/11/2015 |
Mesoblast Limited (ASX:MSB; NASDAQ:MESO) today announced it had listed on the Nasdaq Global Market on 13 November under the symbol "˜MESO | 16/11/2015 |
Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has filed a US registration statement on Form F-1 with the U.S. Securities and Exchange Commission, offering 5,742,510 American Depositary Shares (ADSs) in the United States, with each ADS representing five fully paid ordinary shares of Mesoblast (Shares). The actual number of ADSs and the issue price, in U.S. dollars, will be determined by Mesoblast in conjunction with the Company's underwriters at the conclusion of the offer process. | 03/11/2015 |
Mesoblast Limited (ASX: MSB, USOTC: MBLTY) announced today that it plans to conduct a registered initial public offering in the United States. Mesoblast has previously submitted to the U.S. Securities and Exchange Commission (the "SEC") a draft registration statement. Mesoblast intends to publicly file its registration statement with the SEC and commence the offering next week. | 30/10/2015 |
The company lodges its quarterly report. | 30/10/2015 |
The securities of Mesoblast Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company. Security Code: MSB | 30/10/2015 |
shares reinstated to quotation | 12/05/2010 |
the securities of Mesoblast Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company | 05/05/2010 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 21/04/2025 | Gregory George | 50,000 | $10.438 | $521,917 |
| 10/03/2025 | Gregory George | 74,621 | $1.288 | $96,109 |
| 03/03/2025 | Gregory George | 4,551,282 | $1.593 | $7,251,558 |
| 28/02/2025 | Eric Rose | -196,092 | $2.497 | $489,542 |
| 28/02/2025 | Jane Bell | 79,051 | $2.530 | $199,999 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Jane Bell | Non Exec Chairman | 18/08/2022 |
| Joseph Swedish | Non Exec Chairman | 19/06/2018 |
| William Burns | Vice Chairman | 06/03/2014 |
| Silviu Itescu | Managing Director, CEO | 08/06/2004 |
| Dagmar Rosa-Bjorkeson | COO | 24/07/2020 |
| Andrew Chaponnel | CFO | 30/08/2021 |
| Eric Rose | Director | 17/04/2013 |
| Lyn Cobley | Director | 29/04/2025 |
| Philip Facchina | Director | 29/03/2021 |
| Philip Krause | Director | 24/03/2022 |
| Gregory George | Director | 24/02/2025 |
| Paul Hughes | Company Secretary | |
| Niva Sivakumar | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Michael Spooner | Non Exec Director | 15/08/2005 | 28/09/2023 |
| Shawn Tomasello | Non Exec Director | 11/07/2018 | 18/08/2022 |
| Donal O'Dwyer | Deputy Chairman, Non Exec Director | 29/09/2004 | 27/02/2022 |
| Josh Muntner | CFO | 31/05/2018 | 30/08/2021 |
| Paul Hodgkinson | CFO | 25/08/2014 | 30/08/2021 |
| Brian Jamieson | Non Exec Chairman | 22/11/2007 | 31/03/2019 |
| Ben-Zion Weiner | Non Exec Director | 10/05/2012 | 20/06/2018 |
| Jenni Pilcher | CFO | 01/11/2007 | 31/08/2014 |
| Kevin Buchi | Non Exec Director | 30/12/2010 | 09/05/2012 |
| Byron McAllister | Non Exec Director | 29/09/2004 | 29/11/2010 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
